openPR Logo
Press release

Exploring Opportunities in the Pegfilgrastim Biosimilars Market Size and Growth Trends 2024-2031: An In-depth Forecast |Coherus BioSciences, Mylan N.V., Biocon, Sandoz (a Novartis division)

08-13-2024 08:48 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Pegfilgrastim Biosimilars Market

Pegfilgrastim Biosimilars Market

The latest market intelligence report published by CMI with the title "Global Pegfilgrastim Biosimilars Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Pharmaceutical industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.

The Research report on Pegfilgrastim Biosimilars Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five Forces Analysis, PESTLE Analysis, Value Chain Analysis, 4 Ps' Analysis, Market Attractiveness Analysis, BPS Analysis, Ecosystem Analysis.

Do you think, if this report could be of your interest? If yes, request Sample Copy of this Report: : - https://www.coherentmarketinsights.com/insight/request-sample/7242

*Note: Sample of the report provides details on the scope and coverage, table of contents, research methodology, and Sample Framework of the report. Actual report of 150+ is available for purchase to all the interested stakeholders.

key trends:

Exploding Demand: The increasing prevalence of cancer is fueling demand for biosimilars like Pegfilgrastim that support chemotherapy treatment regimens. Our research shows the market growing at a 9% CAGR through 2031.

Regulatory Harmonization: Recent harmonization of biosimilar approval pathways between regions like the EU and US are lowering market entry barriers - increasing the number of new biosimilar entrants.

Next-Gen Formulations: Leading players like Coherus and Mylan are launching new Pegfilgrastim biosimilars in novel dosage forms like on-body injectors and prefilled syringes for enhanced convenience.

Regional Expansion: Chinese and Indian manufacturers are expanding their Pegfilgrastim biosimilar portfolios and targeting global markets through partnerships with regional distributors.

Want to access more insights? The journey starts from requesting Sample: : - https://www.coherentmarketinsights.com/insight/request-sample/7242

*Note: Sample of the report provides details on the scope and coverage, table of contents, research methodology, and Sample Framework of the report. Actual report of 150+ is available for purchase to all the interested stakeholders.

Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR):

By Product: Pegfilgrastim Biosimilars and Pegfilgrastim Reference Product
By Application: Oncology, Chronic Neutropenia, Stem Cell Transplantation, Others
By Route of Administration: Subcutaneous and Intravenous
By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

• By Regions and Countries

o North America
o Europe
o Asia-Pacific
o South America
o Middle East & Africa

Following are the players analyzed in the report:

◘ Coherus BioSciences
◘ Mylan N.V.
◘ Biocon
◘ Sandoz (a Novartis division)
◘ Pfizer Inc.
◘ Apotex Inc.
◘ Cinfa Biotech
◘ Gedeon Richter
◘ Stada Arzneimittel AG
◘ Mundipharma
◘ Aurobindo Pharma
◘ Glenmark Pharmaceuticals
◘ Dr. Reddy's Laboratories
◘ Intas Pharmaceuticals
◘ Biocad
◘ Genor Biopharma
◘ Qilu Pharmaceutical
◘ Henlius Biotech

Get access to the latest Edition of this Market Study (comprising 150+ pages): : https://www.coherentmarketinsights.com/insight/buy-now/7242

Deep-dive Analysis:

The Report provides deep-dive qualitative and quantitative analysis on Pegfilgrastim Biosimilars Market for all the regions and countries covered below:

➢ North America (the United States, Canada, and Mexico)
➢ Europe (Germany, France, Italy, United Kingdom, SCANDIVAN, Benelux, Russia, and Rest of Europe)
➢ Asia-Pacific (Japan, South Korea, India, China, Southeast Asia, and Australia)
➢ South America (Brazil, Argentina, and Rest of South America)
➢ Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa, and Rest of the Middle East & Africa)
➢ Each Country is covered in detail, and report provides qualitative and quantitative analysis on Pegfilgrastim Biosimilars Market on each country.

The research provides answers to the following key questions:

1.What is the estimated growth rate of the market for the forecast period 2024-2031? What will be the market size during the estimated period?
2.What are the key driving forces responsible for shaping the fate of the Pegfilgrastim Biosimilars market during the forecast period?
3.Who are the major market vendors and what are the winning strategies that have helped them occupy a strong foothold in the Pegfilgrastim Biosimilars market?
4.What are the prominent market trends influencing the development of the Pegfilgrastim Biosimilars market across different regions?
5.What are the major threats and challenges likely to act as a barrier in the growth of the Pegfilgrastim Biosimilars market?
6.What are the major opportunities the market leaders can rely on to gain success and profitability?

Key insights provided by the report that could help you take critical strategic decisions?

• Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
• Reports provide opportunities and threats faced by suppliers in the Pegfilgrastim Biosimilars and tubes industry around the world.
• The report shows regions and sectors with the fastest growth potential.
• A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
• The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
• This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.
• This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

Author of this marketing PR:

Priya Pandey is a dynamic and passionate PR writer with over three years of expertise in content writing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes writing contents and documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)

☎ Contact Us:

Mr. Shah
Senior Client Partner - Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Australia: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exploring Opportunities in the Pegfilgrastim Biosimilars Market Size and Growth Trends 2024-2031: An In-depth Forecast |Coherus BioSciences, Mylan N.V., Biocon, Sandoz (a Novartis division) here

News-ID: 3620895 • Views:

More Releases from Coherent Market Insights

Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abbott Laboratories, Amway, Atkins, Blue Diamond Growers
Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abb …
The Meal Replacement Market is estimated to be valued at USD 14.82 Bn in 2025 and is expected to reach USD 22.01 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Meal Replacement Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion by 2032 with a 7.9% CAGR |C&D Technologies Inc., Crown Battery Manufacturing Co., East Penn Manufacturing Co. Inc., EnerSys
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion …
The deep cycle battery market is estimated to be valued at USD 2.77 billion in 2025 and is expected to reach USD 4.73 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Deep Cycle Battery Market, Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by 2025-2032 |Hangzhou Xunda Packaging Co., Smurfit Kappa Group PLC, DS Smith Plc, Pregis Corporation
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by …
The consumer electronics packaging market is estimated to be valued at USD 26.57 Bn in 2025 and is expected to reach USD 81.72 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Consumer Electronics Packaging Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koninklijke DSM N.V., BAE Systems, Morgan Advanced Materials , Saint-Gobain S.A.
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koni …
The global ceramic armor market is estimated to be valued at USD 2.75 Bn in 2025 and is expected to reach USD 4.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Ceramic Armor Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,

All 5 Releases


More Releases for Pegfilgrastim

Pegfilgrastim Biosimilar Market: Emerging Trends and Growth Forecast to 2033
The global Pegfilgrastim Biosimilar Market, valued at approximately USD 1.56 billion in 2024, is projected to reach around USD 6.36 billion by 2033, growing at a CAGR of 17.1% from 2025 to 2033. Pegfilgrastim Biosimilar Market Overview The Pegfilgrastim Biosimilars Market is experiencing rapid growth due to the increasing prevalence of cancer and the rising demand for cost-effective treatment alternatives to branded biologics. Pegfilgrastim, used to prevent neutropenia in cancer patients undergoing
Global Neulasta (Pegfilgrastim) And Biosimilar Market Size by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Neulasta (Pegfilgrastim) And Biosimilar market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The market for pegfilgrastim and biosimilars is expanding significantly, mostly due to the rising use of chemotherapy-based cancer treatments. By promoting the formation
Global Pegfilgrastim Market Expects 5.8% Growth Rate from 2021-2028 Amid Rising …
According to the latest report published by Dataintelo, the Global Pegfilgrastim Market is projected to expand at a compound annual growth rate (𝐂𝐀𝐆𝐑) of 5.8% during the period between 2021 and 2028. This significant expansion in the market is primarily driven by the escalating number of cancer cases worldwide and an intensified demand for pegfilgrastim biosimilars. The report highlights that the evolving global scenario of cancer management and treatment is fostering
05-04-2021 | Health & Medicine
Fact.MR
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia. Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market Neutropenia patients are highly
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts. Pegfilgrastim is a PEGylated
Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by